Erasca, Inc.
ERAS$563M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO103 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
ERAS News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
Naporafenib
Advanced or Metastatic NRAS-mutant Melanoma
Encorafenib
Metastatic Colorectal Cancer
ERAS-007
Advanced or Metastatic Solid Tumors
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Naporafenib | Phase 3 | Advanced or Metastatic NRAS-mutant Melanoma | - |
Encorafenib | Phase 2 | Metastatic Colorectal Cancer | - |
ERAS-007 | Phase 2 | Advanced or Metastatic Solid Tumors | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply